trial

Interest of EMDR Schizophrenic Disorders

NCTId NCT05164289
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Terminated
Enrollment 6 (actual)
Sponsored by Hôpital NOVO
Primary completion 2022-04-27
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
6 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2021-12-10
Primary completion
2022-04-27
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
EMDR group

Sponsors

Hôpital NOVOLead Sponsor

Investigators

1
Dr Marie-Claire ASMARPrincipal Investigator

Sites

2 total
Pontoise, FranceVillejuif, France

Facts & assertions

4 sourced
Enrollment
6
Phase
NA
Primary Completion Date
2022-04-27
Status
TERMINATED
relationships
The graph out of here
drug
EMDR group
drug
lead_sponsor
Hôpital NOVO
company
indication
Schizophrenic Disorders
indication
Schizophrenia
indication
Psychotic Disorders
indication
investigator
Dr Marie-Claire ASMAR
person